Last Updated: November 8, 2026

TENORMIN Drug Patent Profile

« Back to Dashboard


When do Tenormin patents expire, and what generic alternatives are available?

Tenormin is a drug marketed by Astrazeneca and Twi Pharms and is included in two NDAs.

The generic ingredient in TENORMIN is atenolol. There is one drug master file entry for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the atenolol profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tenormin

A generic version of TENORMIN was approved as atenolol by AIPING PHARM INC on July 15th, 1988.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for TENORMIN?
  • What are the global sales for TENORMIN?
  • What is Average Wholesale Price for TENORMIN?
Summary for TENORMIN
Recent Clinical Trials for TENORMIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Tennessee Medical CenterEarly Phase 1
High Risk Obstetrical ConsultantsEarly Phase 1
University of Tennessee Graduate School of MedicineEarly Phase 1

See all TENORMIN clinical trials

Pharmacology for TENORMIN

US Patents and Regulatory Information for TENORMIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca TENORMIN atenolol INJECTABLE;INJECTION 019058-001 Sep 13, 1989 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Twi Pharms TENORMIN atenolol TABLET;ORAL 018240-002 Approved Prior to Jan 1, 1982 AB RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Twi Pharms TENORMIN atenolol TABLET;ORAL 018240-004 Apr 9, 1990 AB RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TENORMIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Twi Pharms TENORMIN atenolol TABLET;ORAL 018240-001 Approved Prior to Jan 1, 1982 ⤷  Start Trial ⤷  Start Trial
Twi Pharms TENORMIN atenolol TABLET;ORAL 018240-002 Approved Prior to Jan 1, 1982 ⤷  Start Trial ⤷  Start Trial
Twi Pharms TENORMIN atenolol TABLET;ORAL 018240-004 Apr 9, 1990 ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
DrugChatter Q&A for TENORMIN

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.